Oral colchicine in chronic plaque psoriasis

P. Basak, A. Chatterjee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Colchicine is well known for its antimitotic and antiinflammatory effects. This study was designed to evaluate the role of oral colchicine in chronic plaque psoriasis. Fifty adults with chronic plaque psoriasis were randomly allocated into 2 groups of 25 patients each. Group A received oral colchicine 2 mg/day in 2 divided doses, while Group B patients were given placebo tablets. Patients were evaluated every week and the final result compiled after 8 weeks. 90% patients in Group A had gastrointestinal intolerance necessitating a reduction in dose of colchicine to 1 mg/day. After 8 weeks the lesions improved significantly in Group-A patients, compared to Group B (t=2.815, p

Original languageEnglish (US)
Pages (from-to)168-171
Number of pages4
JournalIndian Journal of Dermatology, Venereology and Leprology
Volume59
Issue number4
StatePublished - 1993
Externally publishedYes

Fingerprint

Colchicine
Psoriasis
Antimitotic Agents
Tablets
Anti-Inflammatory Agents
Placebos

ASJC Scopus subject areas

  • Dermatology

Cite this

Oral colchicine in chronic plaque psoriasis. / Basak, P.; Chatterjee, A.

In: Indian Journal of Dermatology, Venereology and Leprology, Vol. 59, No. 4, 1993, p. 168-171.

Research output: Contribution to journalArticle

Basak, P. ; Chatterjee, A. / Oral colchicine in chronic plaque psoriasis. In: Indian Journal of Dermatology, Venereology and Leprology. 1993 ; Vol. 59, No. 4. pp. 168-171.
@article{22f45be3da7d4f2fb60bbb3cb7ae797a,
title = "Oral colchicine in chronic plaque psoriasis",
abstract = "Colchicine is well known for its antimitotic and antiinflammatory effects. This study was designed to evaluate the role of oral colchicine in chronic plaque psoriasis. Fifty adults with chronic plaque psoriasis were randomly allocated into 2 groups of 25 patients each. Group A received oral colchicine 2 mg/day in 2 divided doses, while Group B patients were given placebo tablets. Patients were evaluated every week and the final result compiled after 8 weeks. 90{\%} patients in Group A had gastrointestinal intolerance necessitating a reduction in dose of colchicine to 1 mg/day. After 8 weeks the lesions improved significantly in Group-A patients, compared to Group B (t=2.815, p",
author = "P. Basak and A. Chatterjee",
year = "1993",
language = "English (US)",
volume = "59",
pages = "168--171",
journal = "Indian Journal of Dermatology, Venereology and Leprology",
issn = "0378-6323",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

TY - JOUR

T1 - Oral colchicine in chronic plaque psoriasis

AU - Basak, P.

AU - Chatterjee, A.

PY - 1993

Y1 - 1993

N2 - Colchicine is well known for its antimitotic and antiinflammatory effects. This study was designed to evaluate the role of oral colchicine in chronic plaque psoriasis. Fifty adults with chronic plaque psoriasis were randomly allocated into 2 groups of 25 patients each. Group A received oral colchicine 2 mg/day in 2 divided doses, while Group B patients were given placebo tablets. Patients were evaluated every week and the final result compiled after 8 weeks. 90% patients in Group A had gastrointestinal intolerance necessitating a reduction in dose of colchicine to 1 mg/day. After 8 weeks the lesions improved significantly in Group-A patients, compared to Group B (t=2.815, p

AB - Colchicine is well known for its antimitotic and antiinflammatory effects. This study was designed to evaluate the role of oral colchicine in chronic plaque psoriasis. Fifty adults with chronic plaque psoriasis were randomly allocated into 2 groups of 25 patients each. Group A received oral colchicine 2 mg/day in 2 divided doses, while Group B patients were given placebo tablets. Patients were evaluated every week and the final result compiled after 8 weeks. 90% patients in Group A had gastrointestinal intolerance necessitating a reduction in dose of colchicine to 1 mg/day. After 8 weeks the lesions improved significantly in Group-A patients, compared to Group B (t=2.815, p

UR - http://www.scopus.com/inward/record.url?scp=0027817349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027817349&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027817349

VL - 59

SP - 168

EP - 171

JO - Indian Journal of Dermatology, Venereology and Leprology

JF - Indian Journal of Dermatology, Venereology and Leprology

SN - 0378-6323

IS - 4

ER -